Company intelligence / Profile preview

PuraPharm Corporation Limited

Tai Po, New Territories, Hong Kongpurapharm.com ↗

Ownership: Private
Development stage: Commercial

Overview

PuraPharm has developed Ren Shu Chang Le Granules for Irritable Bowel Syndrome, which received approval for clinical trial by the China Food and Drug Administration (CFDA). Their ONCO-Z ingredient in Oncozac medicinal Yunzhi has been certified by the United States Pharmacopoeia Commission.

Therapeutic areas: Gastroenterology
Modalities: Traditional Chinese Medicine granulesChinese herbal formulas
Industry: Biotech

Drug pipeline

4 assets

Oncozac

3 more assets in the full pipeline.

Partnerships

The Chinese University of Hong KongHong Kong Baptist University

Beyond the preview

Go deeper on PuraPharm Corporation Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PuraPharm Corporation Limited.